Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature

Blood Cells Mol Dis. 2021 Dec:92:102615. doi: 10.1016/j.bcmd.2021.102615. Epub 2021 Oct 7.

Authors

Angelo Gardellini¹, Francesca Guidotti², Elena Maino¹, Sara Steffanoni¹, Michelle Zancanella¹, Mauro Turrini¹

Affiliations

¹ Division of Hematology, Department of Medicine, Valduce Hospital, Como, Italy.
² Division of Hematology, Department of Medicine, Valduce Hospital, Como, Italy. Electronic address: fguidotti@valduce.it.

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

2019-nCoV Vaccine mRNA-1273 / adverse effects*
Adrenal Cortex Hormones / therapeutic use
Adult
BNT162 Vaccine / adverse effects*
COVID-19 / prevention & control*
ChAdOx1 nCoV-19 / adverse effects*
Hashimoto Disease / complications
Hemorrhage / etiology
Humans
Immunoglobulins, Intravenous / therapeutic use
Male
Metabolic Syndrome / complications
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / drug therapy
Purpura, Thrombocytopenic, Idiopathic / etiology*
Recurrence
Rituximab / therapeutic use
SARS-CoV-2*
Vaccination / adverse effects*
Young Adult

Substances

Adrenal Cortex Hormones
Immunoglobulins, Intravenous
Rituximab
ChAdOx1 nCoV-19
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine